Bank of Montreal’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $109K | Hold |
70,000
| – | – | ﹤0.01% | 3115 |
|
|
2025
Q4 | $80.5K | Hold |
70,000
| – | – | ﹤0.01% | 3095 |
|
|
2025
Q3 | $94.5K | Sell |
70,000
-30,000
| -30% | -$34K | ﹤0.01% | 2987 |
|
|
2025
Q2 | $94.6K | Hold |
100,000
| – | – | ﹤0.01% | 2997 |
|
|
2025
Q1 | $46.1K | Buy |
100,000
+30,000
| +43% | +$18.9K | ﹤0.01% | 3086 |
|
|
2024
Q4 | $51.7K | Sell |
70,000
-1
| -0% | -$1 | ﹤0.01% | 3099 |
|
|
2024
Q3 | $112K | Hold |
70,001
| – | – | ﹤0.01% | 3211 |
|
|
2024
Q2 | $125K | Buy |
70,001
+30,000
| +75% | +$53.8K | ﹤0.01% | 3171 |
|
|
2024
Q1 | $87.6K | Buy |
+40,001
| New | +$85.9K | ﹤0.01% | 3309 |
|
|
2022
Q2 | – | Sell |
-12,000
| Closed | -$26K | – | 4286 |
|
|
2022
Q1 | $26K | Buy |
+12,000
| New | +$33.3K | ﹤0.01% | 3891 |
|
|
2021
Q2 | – | Sell |
-1,450
| Closed | -$8K | – | 4396 |
|
|
2021
Q1 | $8K | Sell |
1,450
-4,950
| -77% | -$34.3K | ﹤0.01% | 4461 |
|
|
2020
Q4 | $25K | Buy |
6,400
+4,484
| +234% | +$8.55K | ﹤0.01% | 4318 |
|
|
2020
Q3 | $3K | Sell |
1,916
-1,406
| -42% | -$2.5K | ﹤0.01% | 4579 |
|
|
2020
Q2 | $6K | Buy |
+3,322
| New | +$6.51K | ﹤0.01% | 4376 |
|
|
2020
Q1 | – | Sell |
-5,250
| Closed | -$22K | – | 4433 |
|
|
2019
Q4 | $22K | Buy |
5,250
+1,595
| +44% | +$6.14K | ﹤0.01% | 4267 |
|
|
2019
Q3 | $11K | Sell |
3,655
-9,842
| -73% | -$30.5K | ﹤0.01% | 4379 |
|
|
2019
Q2 | $85K | Buy |
+13,497
| New | +$80.8K | ﹤0.01% | 3444 |
|
|
2019
Q1 | – | Sell |
-605
| Closed | -$3.67K | – | 4557 |
|
|
2018
Q4 | $4K | Sell |
605
-121,448
| -100% | -$984K | ﹤0.01% | 4171 |
|
|
2018
Q3 | $1.3M | Buy |
122,053
+120,611
| +8,364% | +$1.38M | ﹤0.01% | 1891 |
|
|
2018
Q2 | $18K | Buy |
1,442
+1,034
| +253% | +$10.6K | ﹤0.01% | 3779 |
|
|
2018
Q1 | $3K | Hold |
408
| – | – | ﹤0.01% | 3994 |
|
|
2017
Q4 | $4K | Sell |
408
-448
| -52% | -$4.66K | ﹤0.01% | 3963 |
|
|
2017
Q3 | $11K | Sell |
856
-57,933
| -99% | -$856K | ﹤0.01% | 3668 |
|
|
2017
Q2 | $967K | Sell |
58,789
-36,167
| -38% | -$560K | ﹤0.01% | 1996 |
|
|
2017
Q1 | $1.36M | Sell |
94,956
-12,654
| -12% | -$188K | ﹤0.01% | 1738 |
|
|
2016
Q4 | $1.64M | Buy |
107,610
+91,217
| +556% | +$1.46M | ﹤0.01% | 1663 |
|
|
2016
Q3 | $296K | Buy |
16,393
+15,985
| +3,918% | +$257K | ﹤0.01% | 2293 |
|
|
2016
Q2 | $6K | Sell |
408
-150
| -27% | -$2.03K | ﹤0.01% | 3692 |
|
|
2016
Q1 | $7K | Hold |
558
| – | – | ﹤0.01% | 3711 |
|
|
2015
Q4 | $7K | Buy |
558
+408
| +272% | +$5.02K | ﹤0.01% | 3706 |
|
|
2015
Q3 | $2K | Hold |
150
| – | – | ﹤0.01% | 3804 |
|
|
2015
Q2 | $1K | Hold |
150
| – | – | ﹤0.01% | 3841 |
|
|
2015
Q1 | $1K | Hold |
150
| – | – | ﹤0.01% | 3861 |
|
|
2014
Q4 | $1K | Buy |
+150
| New | +$1.21K | ﹤0.01% | 3914 |
|
|
2014
Q3 | – | Sell |
-823
| Closed | -$9K | – | 4235 |
|
|
2014
Q2 | $9K | Buy |
+823
| New | +$8.84K | ﹤0.01% | 3921 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Bank of Montreal's LXRX Position: Q1 2026 in Review
Bank of Montreal held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 70,000 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #3115.
Bank of Montreal first reported a position in LXRX in Q2 2014 and has held it in 35 quarters since. The position peaked at $1.64M in Q4 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Bank of Montreal held 70,000 shares of Lexicon Pharmaceuticals worth $109K as of Q1 2026.
- Bank of Montreal left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
- Lexicon Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #3115 holding.
- Bank of Montreal first reported a position in Lexicon Pharmaceuticals in Q2 2014 and has held it in 35 quarters since.
- Bank of Montreal's Lexicon Pharmaceuticals position peaked at $1.64M in Q4 2016.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.